Relative risk models including all five high risk factors.

Relative risk models including all five high risk factors.</p

Predefined NSAID-associated upper gastrointestinal adverse events.

Predefined NSAID-associated upper gastrointestinal adverse events.</p

Proportion of patients with NSAID-associated upper gastrointestinal adverse events under naproxen treatment (n = 426).

Proportion of patients with NSAID-associated upper gastrointestinal adverse events under naproxen treatment (n = 426).</p

SODA pain intensity scores of patients who had an ulcer either at the final visit of the study (6 months) or at premature study exit for any other reason or completed the study without ulcer.

Data are number of patients. SODA, Severity of Dyspepsia Assessment.</p

Patient demographics and baseline characteristics of the two trial populations receiving enteric-coated naproxen (pooled data; safety set).

Patient demographics and baseline characteristics of the two trial populations receiving enteric-coated naproxen (pooled data; safety set).</p

SODA pain intensity scores preceding ulcer development stratified by ulcer development at baseline, 1 month, and 3 months of treatment with naproxen.

Data are number of patients. SODA, Severity of Dyspepsia Assessment.</p

Ulcer development under naproxen treatment (n = 426).

Ulcer development under naproxen treatment (n = 426).</p

Influence of the number of risk factors on ulcer development (n = 426).

Influence of the number of risk factors on ulcer development (n = 426).</p

The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test

<div><p>Background</p><p>Clinically significant portal hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥10 mmHg, causes major complications. HVPG is not always available, so a non-invasive tool to diagnose CSPH would be useful. VWF-Ag can be used to diagnose. Using the VITRO score (the VWF-Ag/platelet ratio) instead of VWF-Ag itself improves the diagnostic accuracy of detecting cirrhosis/ fibrosis in HCV patients.</p><p>Aim</p><p>This study tested the diagnostic accuracy of VITRO score detecting CSPH compared to HVPG measurement.</p><p>Methods</p><p>All patients underwent HVPG testing and were categorised as CSPH or no CSPH. The following patient data were determined: CPS, D’Amico stage, VITRO score, APRI and transient elastography (TE).</p><p>Results</p><p>The analysis included 236 patients; 170 (72%) were male, and the median age was 57.9 (35.2–76.3; 95% CI). Disease aetiology included ALD (39.4%), HCV (23.4%), NASH (12.3%), other (8.1%) and unknown (11.9%). The CPS showed 140 patients (59.3%) with CPS A; 56 (23.7%) with CPS B; and 18 (7.6%) with CPS C. 136 patients (57.6%) had compensated and 100 (42.4%) had decompensated cirrhosis; 83.9% had HVPG ≥10 mmHg. The VWF-Ag and the VITRO score increased significantly with worsening HVPG categories (P<0.0001). ROC analysis was performed for the detection of CSPH and showed AUC values of 0.92 for TE, 0.86 for VITRO score, 0.79 for VWF-Ag, 0.68 for ELF and 0.62 for APRI.</p><p>Conclusion</p><p>The VITRO score is an easy way to diagnose CSPH independently of CPS in routine clinical work and may improve the management of patients with cirrhosis.</p></div

ROC analysis shows the ability of aspartate aminotransferase to platelet ratio index (APRI) predicting clinically significant portal hypertension (CSPH).

<p>ROC analysis showing the diagnostic ability of APRI detecting CSPH with an AUC of 0.62.</p